Volume 2, Issue 3
Editorialp. 227-229
Electronic health records and clinical trials research in the digital age
Author(s): Elizabeth M Borycki, Andre W Kushniruk
Interviewp. 235-240
Perspective on Adaptive Designs: 4 years European Medicines Agency reflection paper, 1 year draft US FDA guidance: where are we now?
Author(s): Brenda Gaydos, Armin Koch, Frank Miller, Martin Posch, Marc Vandemeulebroecke, Sue-Jane Wang
News and Viewsp. 241-243
New treatment for Cushins disease given European Medicines Agency recommendation
Research Updatep. 245-254
HIV Vaccine Trials Network: activities and achievements of the first decade and beyond
Author(s): James G Kublin, Cecilia A Morgan, Tracey A Day, Peter B Gilbert, Steve G Self, M Juliana McElrath & Lawrence Corey
Research Updatep. 255-264
Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience
Author(s): Frank de Wolf, Caroline Sabin, Ole Kirk, Claire Thorne, Genevieve Chene,Kholoud Porter
Clinical Trail Perspectivep. 265-273
Assessment of suicidal ideation and behavior in clinical trials: challenges & controversies
Author(s): Glenn Melvin
Clinical Trail Perspectivep. 275-289
Statistical design and analysis issues for the ARDS clinical trials network: the Coordinating Center perspective
Author(s): David Schoenfeld
Clinical Trail Perspectivep. 291-300
Challenges of developing new drugs for childhood cancers
Author(s): Frank M Balis, Elizabeth Fox
Therapeutic Perspectivep. 301-315
Therapeutic potential of c-MET inhibitors: background and clinical data
Author(s): Shawna Leslie Organ, J Rafael Sierra,Ming-Sound Tsao
Review: Clinical Trail Outcomesp. 317-325
Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence
Author(s): Deme John Karikios & Michael Joseph Boyer
Special Reportp. 327-336
The views of older people and carers on participation in clinical trials: the PREDICT Study
Author(s): Frank Balis
